Alivus Life Sciences Ltd.

Glenmark Life Sciences has reported results for first quarter ended June 30, 2024 (Q1FY25). 

The company has reported 17.70% fall in net profit at Rs 111.48 crore for Q1FY25 as compared to Rs 135.45 crore for the same quarter in the previous year. However, total income of the company increased by 2.38% at Rs 594.11 crore for Q1FY25 as compared to Rs 580.30 crore for the corresponding quarter previous year.

Glenmark Life Sciences is in the business of making high-quality drugs by unlocking the possibilities of science.